- Home
- STCN vs BCAB Comparison
STCN vs BCAB Comparison
Compare STCN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- BCAB
- Stock Information
- Founded
- STCN 1986
- BCAB 2007
- Country
- STCN United States
- BCAB United States
- Employees
- STCN N/A
- BCAB N/A
- Industry
- STCN Advertising
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- STCN Consumer Discretionary
- BCAB Health Care
- Exchange
- STCN Nasdaq
- BCAB Nasdaq
- Market Cap
- STCN 63.4M
- BCAB 96.2M
- IPO Year
- STCN 1994
- BCAB 2020
- Fundamental
- Price
- STCN $10.40
- BCAB $2.08
- Analyst Decision
- STCN
- BCAB Strong Buy
- Analyst Count
- STCN 0
- BCAB 2
- Target Price
- STCN N/A
- BCAB $6.00
- AVG Volume (30 Days)
- STCN 11.9K
- BCAB 1.6M
- Earning Date
- STCN 12-12-2024
- BCAB 11-08-2024
- Dividend Yield
- STCN N/A
- BCAB N/A
- EPS Growth
- STCN 203.29
- BCAB N/A
- EPS
- STCN 3.17
- BCAB N/A
- Revenue
- STCN $169,044,000.00
- BCAB N/A
- Revenue This Year
- STCN N/A
- BCAB N/A
- Revenue Next Year
- STCN N/A
- BCAB N/A
- P/E Ratio
- STCN $3.19
- BCAB N/A
- Revenue Growth
- STCN N/A
- BCAB N/A
- 52 Week Low
- STCN $7.36
- BCAB $1.14
- 52 Week High
- STCN $13.00
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- STCN 57.19
- BCAB 55.80
- Support Level
- STCN $9.90
- BCAB $1.87
- Resistance Level
- STCN $10.29
- BCAB $2.13
- Average True Range (ATR)
- STCN 0.39
- BCAB 0.12
- MACD
- STCN 0.11
- BCAB 0.00
- Stochastic Oscillator
- STCN 100.00
- BCAB 68.90
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.